Researchers found that bioengineered CAR-T cells when mixed with other immune cells can "donate" proteins, suggesting ...

Allogene Therapeutics, Inc. ALLO announced that the FDA has cleared its investigational new drug (IND) application to begin ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...

For instance, this location could be a tumor site where CRISPR needs to be used to modify the DNA of cancer cells to make them more susceptible to attack from CAR T-cell-based immunotherapy.

Unleashing CRISPR on Cancer: In this episode of “Intention ... with the investigator who developed the “off-the-shelf” CAR T cells that made her treatment possible.

Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications; Inno ...

Moreover, Crispr Therapeutics has reported encouraging initial clinical data from its Phase I/II trial of CTX112, an allogeneic CAR-T therapy for CD19-positive B-cell malignancies, highlighting ...

ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.